Chronic Lymphocytic Leukemia | Specialty

Japan Approves Acalabrutinib for Treatment-Naïve CLL

January 6th 2023

Japan’s Ministry of Health, Labor, and Welfare has approved acalabrutinib for the treatment of previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

January 6th 2023

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

January 5th 2023

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Driven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.

Lisaftoclax With or Without Rituximab or Acalabrutinib Elicits Favorable Responses and Safety in CLL/SLL

December 23rd 2022

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL

December 19th 2022

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL

December 15th 2022

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.

BGB-11417 Alone or in Combination with Zanubrutinib Shows Early Efficacy in CLL/SLL

December 13th 2022

BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.

Unveiling Practice-Changing Data in CLL, GVHD, and MPNs: Drs Catherine Coombs, Nelli Bejanyan, and Aaron Gerds

December 13th 2022

Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL

December 13th 2022

Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable Tolerability in MCL and CLL

December 11th 2022

The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Rhodes on Evaluating the Unmet Needs of Elderly Patients in CLL

December 2nd 2022

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

European Commission Approves Zanubrutinib for CLL

November 18th 2022

The European Commission has approved zanubrutinib for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia.

Closing Remarks on Unmet Needs in R/R FL

November 10th 2022

Dr Hill closes by discussing current unmet needs in the R/R FL landscape and giving practical advice to providers caring for patients with FL.

CAR T-cell Options for Patients with R/R FL

November 10th 2022

A focused discussion on available CAR T-cell therapies for patients with R/R FL, supporting efficacy data, and how these therapies have impacted the field.

Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development

November 9th 2022

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Dr. Awan on Selecting BTK Inhibitors for CLL Management

November 7th 2022

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Ibrutinib Demonstrates Long-Term Efficacy in CLL in Real-World Setting

November 3rd 2022

Ibrutinib induced a cumulative overall response rate of 90.0% in 3-year findings from the Belgian Ibrutinib Real‑World Data study of patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia.

Considerations for Treatment Selection in the Third-Line R/R FL Setting

November 3rd 2022

Dr Hill shares how he would have handled the patient case and discusses factors that contribute to treatment selection among third-line therapies for patients with R/R FL, including axicabtagene ciloleucel and other CAR T-cell therapies.